Functional selection of hepatitis C virus envelope E2-binding peptide ligands by using ribosome display

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3355-3364

  Chen, Fang ^a   Zhao, Yinglan ^a   Liu, Min ^a   Li, Dongqing ^a   Wu, Hongyan ^a,e   Chen, Haidan ^a   Zhu, Yongzhe ^b   Luo, Fengling ^a   Zhong, Jin ^c   Zhou, Yidan ^d   Qi, Zhongtian ^b   Zhang, Xiao Lian ^a  

^a WUHAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c INSTITUTE PASTEUR OF SHANGHAI   (China)

^d JIANGHAN UNIVERSITY   (China)

^e CHINA THREE GORGES UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE E2 BINDING PEPTIDE; ENVELOPE PROTEIN; PEPTIDE LIBRARY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; CELL FREE SYSTEM; CONTROLLED STUDY; DIAGNOSTIC VALUE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL; MOLECULAR PROBE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RIBOSOME; VIRUS CULTURE; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; HEPACIVIRUS; HEPATOCYTES; HUMANS; LIGANDS; MOLECULAR PROBES; PEPTIDE LIBRARY; PEPTIDES; RIBOSOMES; VIRAL ENVELOPE PROTEINS;

EID: 77955350044     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01357-09     Document Type: Article

References (60)

1. Amstutz, P., P. Forrer, C. Zahnd, and A. Pluckthun. 2001. In vitro display technologies: novel developments and applications. Curr. Opin. Biotechnol. 12:400-405.
2. Barth, H., C. Schäfer, M. I. Adah, F. Zhang, R. J. Linhardt, H. Toyoda, A. K. Toyoda, T. Toida, T. H. Kuppevelt, E. Depla, F. von Weizsäcker, H. E. Blum, and T. F. Baumert. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278: 41003-41012.
3. Bartosch, B., A. Vitelli, C. Granier, C. Goujon, J. Dubuisson, S. Pascale, E. Scarselli, R. Cortese, A. Nicosia, and F. L. Cosset. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278:41624-41630.
4. Binz, H. K., P. Amstutz, A. Kohl, M. T. Stumpp, C. Briand, P. Forrer, M. G. Grütter, and A. Plückthun. 2004. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat. Biotechnol. 22:575-582.
5. Boder, E. T., and K. D. Wittrup. 1997. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15:553-557.
6. Boyer, N., and P. Marcellin. 2000. Pathogenesis, diagnosis and management of hepatitis C. J. Hepatol. 32:98-112.
7. Cao, J., P. Zhao, X. H. Miao, L. J. Zhao, L. J. Xue, and Z. Z. Qi. 2003. Phage display selection on whole cells yields a small peptide specific for HCV receptor human CD81. Cell Res. 13:473-479.
8. Chen, F., Y. Hu, D. Li, H. Chen, and X. L. Zhang. 2009. CS-SELEX generates high-affinity ssDNA aptamers as molecular probes for hepatitis C virus envelope glycoprotein E2. PLoS One 4:e8142.
9. Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
10. Cocquerel, L., C. Voisset, and J. Dubuisson. 2006. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol. 87:1075-1084.
11. Cull, M. G., J. F. Miller, and P. J. Schatz. 1992. Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor. Proc. Natl. Acad. Sci. U. S. A. 89:1865-1869.
12. De Cock, L., V. Hutse, and R. Vranckx. 2005. Correlation between detection of antibodies against hepatitis C virus in oral fluid and hepatitis C virus RNA in serum. Eur. J. Clin. Microbiol. Infect. Dis. 24:566-568.
13. Dower, W. J., and L. C. Mattheakis. 2002. In vitro selection as a powerful tool for the applied evolution of proteins and peptides. Curr. Opin. Chem. Biol. 6:390-398.
14. Dunn, I. S. 1996. Phage display of proteins. Curr. Opin. Biotechnol. 7:547-553.
15. Evans, M. J., T. von Hahn, N. M. Tscherne, A. J. Svder, M. Panis, B. Wolk, T. Hatziioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805. (Pubitemid 46582027)
16. Fields, S., and O. Song. 1989. A novel genetic system to detect proteinprotein interactions. Nature 340:245-246. (Pubitemid 19171591)
17. Flint, M., and J. A. McKeating. 2000. The role of the hepatitis C virus glycoproteins in infection. Rev. Med. Virol. 10:101-117.
18. Flint, M., T. von Hahn, J. Zhang, M. Farquhar, C. T. Jones, P. Balfe, C. M. Rice, and J. A. McKeating. 2006. Diverse CD81 proteins support hepatitis C virus infection. J. Virol. 80:11331-11342. (Pubitemid 44706573)
19. Gersuk, G. M., M. J. Corey, F. Corey, J. E. Stray, G. H. Kawasaki, and R. L. Vessella. 1997. High-affinity peptide ligands to prostate-specific antigen identified by polysome selection. Biochem. Biophys. Res. Commun. 232:578-582.
20. Gottwein, J. M., T. K. Scheel, T. B. Jensen, J. B. Lademann, J. C. Prentoe, M. L. Knudsen, A. M. Hoegh, and J. Bukh. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377.
21. Grove, J., S. Nielsen, J. Zhong, M. F. Bassendine, H. E. Drummer, P. Balfe, and J. A. McKeating. 2008. Identification of a resident in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J. Virol. 82:12020-12029.
22. Grove, J., T. Huby, Z. Stamataki, T. Vanwolleghem, P. Meuleman, M. Farquhar, A. Schwarz, M. Moreau, J. S. Owen, G. Leroux-Roels, P. Balfe, and J. A. McKeating. 2007. Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J. Virol. 81:3162-3169. (Pubitemid 46456625)
23. Hanes, J., and A. Pluckthun. 1997. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. U. S. A. 94:4937-4942.
24. Hanes, J., C. Schatzel, A. Knappik, and A. Pluckthun. 2000. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol. 18:1287-1292.
25. Harris, H. J., M. J. Farquhar, C. J. Mee, C. Davis, G. M. Reynolds, A. Jennings, K. Hu, F. Yuan, H. Deng, S. G. Hubscher, J. H. Han, P. Balfe, and J. A. McKeating. 2008. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J. Virol. 82:5007-5020.
26. He, M., and M. J. Taussig. 2007. Rapid discovery of protein interactions by cell-free protein technologies. Biochem. Soc. Trans. 35:962-965.
27. Irving, R. A., G. Coia, A. Roberts, S. D. Nuttall, and P. J. Hudson. 2001. Ribosome display and affinity maturation: from antibodies to single Vdomains and steps towards cancer therapeutics. J. Immunol. Methods 248:31-45.
28. Jermutus, L., A. Honegger, F. Schwesinger, J. Hanes, and A. Plückthun. 2001. Tailoring in vitro evolution for protein affinity or stability. Proc. Natl. Acad. Sci. U. S. A. 98:75-80.
29. Keefe, A. D. 2001. Protein selecting using mRNA display. Curr. Protoc. Mol. Biol. Unit 24.5, p. 24.5.1-24.5.34. doi:10.1002/0471142727.mb2405s53.
30. Kita, M., M. Deguchi, M. Kagita, N. Yoshioka, E. Kobayashi, M. Watanabe, S. Asari, K. Yamanaka, and Y. Iwatani. 2009. Clinical utility and characteristics of nine anti-HCV antibody screening reagents used in Japan. Clin. Lab. 55:9-22.
31. Koutsoudakis, G., E. Herrmann, S. Kallis, R. Bartenschlager, and T. Pietschmann. 2007. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 81:588-598. (Pubitemid 46067886)
32. Lamla, T., and V. A. Erdmann. 2003. Searching sequence space for highaffinity binding peptides using ribosome display. J. Mol. Biol. 329:381-388.
33. Li, P., Q. Wan, Y. Feng, M. Liu, J. G. Wu, X. W. Chen, and X. L. Zhang. 2007. Engineering of N-glycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine 25:1544-1551. (Pubitemid 46074287)
34. Lindenbach, B. D., and C. M. Rice. 2003. Molecular biology of flaviviridae. Adv. Virus Res. 59:23-61.
35. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wölk, T. L. Tellinghuisen, C. C. Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
36. Mattheakis, L. C., R. R. Bhatt, and W. J. Dower. 1994. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc. Natl. Acad. Sci. U. S. A. 91:9022-9026.
37. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht. 1998. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1485-1492.
38. Meuleman, P., J. Hesselgesser, M. Paulson, T. Vanwolleghem, I. Desombere, H. Reiser, and G. Leroux-Roles. 2008. Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo. Hepatology 48:1761-1768.
39. Mondon, P., O. Dubreuil, K. Bouayadi, and H. Kharrat. 2008. Human antibody libraries: a race to engineer and explore a large diversity. Front. Biosci. 13:1117-1129.
40. Murphy, M., L. Jason-Moller, and J. Bruno. 2006. Using Biacore to measure the binding kinetics of an antibody-antigen interaction. Curr. Protoc. Protein Sci. Chapter 19, Unit 19.14. doi:10.1002/0471142301.ps1914s45.
41. Owsianka, A. M., J. M. Timms, A. W. Tarr, R. J. Brown, T. P. Hickling, A. Szwejk, K. Bienkowska-Szewczyk, B. J. Thomson, A. H. Patel, and J. K. Ball. 2006. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 80:8695-8704.
42. Penin, F., C. Combet, G. Germanidis, P. O. Frainais, G. Deléage, and J. M. Pawlotsky. 2001. Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J. Virol. 75:5703-5710. (Pubitemid 32488166)
43. Pietschmann, T. 2009. Virology: final entry key for hepatits C virus. Nature 457(7231):797-798.
44. Ploss, A., M. J. Evans, V. A. Gaysinskaya, M. Panis, H. You, Y. P. de Jong, and C. M. Rice. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231):882-886.
45. Poynard, T., P. Marcellin, S. S. Lee, C. Niederau, G. S. Minuk, and G. Ideo. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 352:1426-1432.
46. Roccasecca, R., H. Ansuini, A. Vitelli, A. Meola, E. Scarselli, S. Acali, M. Pezzanera, B. B. Ercole, J. McKeating, A. Yagnik, A. Lahm, A. Tramontano, R. Cortese, and A. Nicosia. 2003. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J. Virol. 77:1856-1867.
47. Rothwangl, K. B., B. Manicassamy, S. L. Uprichard, and L. Rong. 2008. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding. Virol. J. 5:46.
48. Schwarz, A. K., J. Grove, K. Hu, C. J. Mee, P. Balfe, and J. A. McKeating. 2009. Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. J. Virol. 83:12407-12414.
49. Shangguan, D. H., Y. Li, Z. W. Tang, Z. C. Cao, H. W. Chen, P. Mallikaratchy, K. Sefah, C. J. Yang, and W. Tan. 2006. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. U. S. A. 103:11838-11843.
50. Smith, G. P., and V. A. Petrenko. 1997. Phage display. Chem. Rev. 97:391-410.
51. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
52. Weichhart, T., M. Horky, J. Söllner, S. Gangl, T. Henics, E. Nagy, A. Meinke, A. von Gabain, C. M. Fraser, S. R. Gill, M. Hafner, and U. von Ahsen. 2003. Functional selection of vaccine candidate peptides from Staphylococcus aureus whole-genome expression libraries in vitro. Infect. Immun. 71:4633-4641.
53. Wu, H. Y., X.-L. Zhang, Q. Pan, and J. Wu. 2005. Functional selection of a type IV pili-binding peptide that specifically inhibits Salmonella typhi adhesion to/invasion of human monocytic cells. Peptide 26:2057-2063.
54. Wünschmann, S., J. D. Medh, D. Klinzmann, W. N. Schmidt, and J. T. Stapleton. 2000. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J. Virol. 74:10055-10062.
55. Yang, L. M., J. L. Wang, L. Kang, S. Gao, Y. H. Liu, and T. M. Hu. 2008. Construction and analysis of high-complexity ribosome display random peptide libraries. PLoS One 3:e2092.
56. Yang, J. H., J. P. Lai, S. D. Douglas, D. Metzger, X. H. Zhu, and W.-Z. Ho. 2002. Real-time RT-PCR for quantitation of hepatitis C virus RNA. J. Virol. Methods 102:119-128.
57. Yu, H., and J. F. Talts. 2003. Beta1 integrin and alpha-dystroglycan binding sites are localized to different laminin-G-domain-like (LG) modules within the laminin alpha5 chain G domain. Biochem. J. 371(Pt. 2):289-299. (Pubitemid 36547611)
58. Zahnd, C., P. Amstutz, and A. Plückthun. 2007. Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target. Nat. Methods 4:269-279. (Pubitemid 46358879)
59. Zhang, J., G. Randall, A. Higginbottom, P. Monk, C. M. Rice, and J. A. McKeating. 2004. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 78:1448-1455. (Pubitemid 38095855)
60. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299.